State of Wisconsin Investment Board Sells 3,931 Shares of Amgen Inc. $AMGN

State of Wisconsin Investment Board lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 278,964 shares of the medical research company’s stock after selling 3,931 shares during the period. State of Wisconsin Investment Board’s holdings in Amgen were worth $91,308,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Captrust Financial Advisors increased its holdings in shares of Amgen by 2.6% in the 4th quarter. Captrust Financial Advisors now owns 498,265 shares of the medical research company’s stock worth $163,087,000 after buying an additional 12,562 shares during the last quarter. Fred Alger Management LLC increased its holdings in shares of Amgen by 63.1% in the 4th quarter. Fred Alger Management LLC now owns 13,258 shares of the medical research company’s stock worth $4,339,000 after buying an additional 5,130 shares during the last quarter. &PARTNERS increased its holdings in shares of Amgen by 14.1% in the 4th quarter. &PARTNERS now owns 279,569 shares of the medical research company’s stock worth $91,583,000 after buying an additional 34,537 shares during the last quarter. Blair William & Co. IL increased its holdings in shares of Amgen by 1.2% in the 4th quarter. Blair William & Co. IL now owns 164,196 shares of the medical research company’s stock worth $53,743,000 after buying an additional 1,957 shares during the last quarter. Finally, Berkshire Asset Management LLC PA increased its holdings in shares of Amgen by 1.3% in the 4th quarter. Berkshire Asset Management LLC PA now owns 27,236 shares of the medical research company’s stock worth $8,915,000 after buying an additional 356 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $347.84 on Wednesday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The firm’s fifty day moving average is $341.02 and its 200 day moving average is $345.89. The firm has a market cap of $187.73 billion, a P/E ratio of 24.21, a P/E/G ratio of 3.52 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the firm earned $4.90 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts predict that Amgen Inc. will post 22.38 earnings per share for the current year.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on AMGN shares. Argus decreased their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday. Mizuho increased their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a report on Tuesday. Daiwa Securities Group decreased their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Finally, UBS Group increased their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.